|
|
Post by proctologistpete on Nov 1, 2013 11:29:09 GMT -5
MNKD's back is against the wall. Any deal they potentially get will be willy nilly. An exec at a BP said afrezza will be a niche drug. MNKD cannot take this drug to market by themselves and any potential partner knows that, therefore MNKD has no leverage in negotiations. There's no guarantee the FDA will approve this drug, and even if approved the approval could be limited to type 1's. A lot of uncertainty about commercial viability, approval, partnership deals. This equates to a falling stock price. Get used to it. I expect to see MNKD back in the $3's soon.
Oh yes, the upcoming CC - the same old bs from mngt.
|
|
|
|
Post by liane on Nov 1, 2013 11:53:38 GMT -5
proctologistpete,
Welcome to the board. Aren't you just a dark cloud! Certainly you're entitled to your opinion. I don't happen to share it. Certainly the share price has been highly manipulated, but that doesn't reflect the eventual potential of Afrezza and MNKD. Good luck with your short (not). Maybe next time you can provide some DD with your post.
|
|
|
|
Post by rak5555 on Nov 1, 2013 13:01:56 GMT -5
"MNKD's back is against the wall."
With a name like "proctologistpete", who can blame them?
|
|
|
|
Post by slushy on Nov 1, 2013 14:01:21 GMT -5
I always like when someone says "they have no leverage in negotiations"... except a product that could make the partnering company billions in revenue. But you keep on with your unsubstantiated bashing, good to see you migrate from YMB
|
|
|
|
Post by liane on Nov 1, 2013 14:30:13 GMT -5
I always like when someone says "they have no leverage in negotiations"... except a product that could make the partnering company billions in revenue. But you keep on with your unsubstantiated bashing, good to see you migrate from YMB That's exactly the point slushy. Multibillion dollar income stream for many years to come. Who wouldn't want that. |
|
|
|
Post by spiro on Nov 1, 2013 15:00:22 GMT -5
Good grief, an estimated 336 million people in the world have diabetes today, with that number expected to grow to over 552 million by 2030. Almost every major pharmaceutical company has it's eye on this market now. Do you think MNKD is in the right place, at the right time with it's potential game changing Afrezza. "YES" Longs will need some patience, but when our celebration occurs, it will be a big one. www.idf.org/diabetesatlas/5e/the-global-burden |
|
|
|
Post by mdcenter61 on Nov 1, 2013 16:13:04 GMT -5
MNKD's back is against the wall. Any deal they potentially get will be willy nilly. An exec at a BP said afrezza will be a niche drug. MNKD cannot take this drug to market by themselves and any potential partner knows that, therefore MNKD has no leverage in negotiations. There's no guarantee the FDA will approve this drug, and even if approved the approval could be limited to type 1's. A lot of uncertainty about commercial viability, approval, partnership deals. This equates to a falling stock price. Get used to it. I expect to see MNKD back in the $3's soon. Oh yes, the upcoming CC - the same old bs from mngt. Thanks for your wonderful wit and insight, Proc, I can only assume you have had a long week looking at and prodding hind ends. I really don't expect any earth shattering news on Monday, and my investment horizon for this stock goes out well into the future. Even though there has been a little price slippage lately, there always are buyers for those sellers. I hope you cover your short position soon and enjoy your weekend - those hind ends will be waiting on you on Monday. |
|
|
|
Post by liane on Nov 1, 2013 16:30:46 GMT -5
proctologistpete,
It's been noted that you are registered under multiple IDs on this board. Please notify me which one you prefer to use so I can delete any others. If you fail to notify me, the choice will be made for you.
liane (admin)
|
|
|
|
Post by mannmade on Nov 1, 2013 19:49:28 GMT -5
Proc, the great thing about this country is that everyone is entitled to their opinion... even when they don't understand the science. Should you take the time to educate yourself you may come to the same conclusions but at least it would be an educated conversation. Yes this company and this drug have had several setbacks in the quest/journey for approval, but that is exactly the strength of their current position. They have learned from their mistakes and now they are better prepared to conquer the three remaining issues, 1.) partnership, 2.) FDA approval and 3.) Professional Medical and Consumer acceptance. And neither 1 or 3 is a deal killer just changes the pace of growth. Btw, you might look to see the list of past issues that are now non issues having been addressed and overcome. Now we are down to three and the good news is we will have our answers within the next 5 1/2 months... The science is good, no one can dispute this now and so even the most ardent detractors admit that Afrezza will likely get FDA approval. And by the way the studies were designed in such a way that the real benefits of Afrezza have yet to be validated and that is the ability to potentially lower fasting glucose levels which may slow or perhaps stop the progression of the disease. So take a rest and watch.... and if you don't have the patience then sell so I can buy more. I am long with an extremely large number of shares and continue to buy on these down trends as I have been doing for the last four years...
|
|
|
|
Post by mannmade on Nov 1, 2013 19:54:16 GMT -5
btw who was the executive and what was the name of the "large BP" that said Afrezza would be a niche drug? The same guy who wrote the Summer Street article that there was a good chance the NDA would not be accepted by the FDA? When stating facts please back them up. I can also tell you that the head of Pfizers Diabetes Division in a recent interview stated that Afrezza is far superior to Exhubera and that they made mistakes with not just the delivery device but only focusing on inhalation aspects and not bettering the drug itself.
|
|
|
|
Post by nadathing on Nov 1, 2013 21:12:29 GMT -5
I hope there is no good news at the conference call. We can't afford to have the share price drop again. LOL. This is maddening. I took a bold step by increasing my position this week. At some point I truly believe huge gains will be made, but it is obvious that forces are working against this stock.
|
|
|
|
Post by mannmade on Nov 1, 2013 21:29:16 GMT -5
Accumulating wealth is not easy... It is mostly a long term process with certain exceptions... Getting people to to the right thing can be even tougher...
|
|
|
|
Post by alcc on Nov 1, 2013 22:52:38 GMT -5
Oh god. The low lives of YMB invading our oasis of sanity.
Moderator, please exercise your discretion.
|
|
|
|
Post by liane on Nov 2, 2013 4:51:59 GMT -5
If anyone has any doubts as to the rules of this message board, there's a link at the top of the Home page. We do allow views on all sides, but no groundless pumping, bashing, or spam. This board is meant to share knowledge and well thought out opinions, not nonsense. When posters break the rules, we do intervene - usually gently at first, but more harshly if the behavior continues. The exception is major infractions (spam, porn etc) - this gets an immediate ban.
That said, we try not to be heavy-handed. We want everyone to have fun. There are also specific boards where you can post off-topic and humorous stuff.
|
|
|
|
Post by babaoriley on Nov 2, 2013 12:24:45 GMT -5
No porn?
|
|
